Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > kly

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Apr 28, 2020 7:27pm

179 Views

Post# 30964211

RE:RE:RE:RE:RE:RE:kly

DoubleD wrote: I hope you're right moonshine, I truly do but this whole smells bad.

Here's more food for thought:

A number of investment firms in Europe are closed because of COVID ... If we had a European suitor interested in partnering with Kaly - (given they have an EU patent) ...it would make sense that their funds would be delayed during this time ...

Further - (as someone already pointed out) - Why announce a deal or partnership during a lockdown?

Doesn't "smell bad" to me ... hang in there .. and most of all don't sell - at least not at this point in time ..

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment